Global News and Digital Insights
for the Healthcare Industry

Antibacterial drug ‘clofoctol’ may counter coronavirus, research from the Pasteur Institute in Lille suggests

Clofoctol, an antibacterial drug, may be a potential treatment for SARS-CoV-2 virus, suggests the Pasteur Institute in Lille, France. The existing drug is currently used for bacterial respiratory tract infections and infections caused after nose, throat, or ear surgeries. Head of the Center for Infection and Immunity of Lille, Dr. Jean Dubuisson, informs that clofoctol has the potential to run a clinical trial because evidence suggests that it has anti-SARS-CoV-2 properties.

Read More from MedicalNewsToday

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn